Calliditas Therapeutics AB (publ)
CALT · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.72 | -0.00 | 1.06 | -0.10 |
| FCF Yield | -0.06% | -3.26% | 0.14% | -1.17% |
| EV / EBITDA | -389.04 | -30.98 | 217.14 | -33.54 |
| Quality | ||||
| ROIC | -2.89% | -15.85% | 2.52% | -12.92% |
| Gross Margin | 90.45% | 95.26% | 95.06% | 94.94% |
| Cash Conversion Ratio | 0.15 | 0.97 | -1.24 | 0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | 67.12% | 67.48% | 73.94% | 81.35% |
| Free Cash Flow Growth | 96.45% | -2,070.82% | 116.08% | 61.65% |
| Safety | ||||
| Net Debt / EBITDA | -7.32 | -1.02 | 0.17 | 0.11 |
| Interest Coverage | -3.06 | -4.69 | 0.00 | -35.39 |
| Efficiency | ||||
| Inventory Turnover | 1.33 | 0.48 | 1.09 | 0.93 |
| Cash Conversion Cycle | -135.69 | -384.01 | -285.93 | -237.36 |